Gene Therapy for Rheumatoid Arthritis

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))

(2010) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)

(2010) G. R. Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute-phase reactants

(2010) Josef S. Smolen et al.   ARTHRITIS AND RHEUMATISM

Getting arthritis gene therapy into the clinic

(2010) Christopher H. Evans et al.   Nature Reviews Rheumatology

Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)

(2010) A. Rubbert-Roth et al.   RHEUMATOLOGY

In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance

(2009) A. Annoni et al.   BLOOD

State-of-the-Art Lentiviral Vectors for Research Use: Risk Assessment and Biosafety Recommendations

(2009) Katia Pauwels et al.   CURRENT GENE THERAPY

Clinical Responses to Gene Therapy in Joints of Two Subjects with Rheumatoid Arthritis

(2009) Peter Wehling et al.   HUMAN GENE THERAPY

Safety, Tolerability, and Clinical Outcomes after Intraarticular Injection of a Recombinant Adeno-associated Vector Containing a Tumor Necrosis Factor Antagonist Gene: Results of a Phase 1/2 Study

(2009) P. J. MEASE et al.   JOURNAL OF RHEUMATOLOGY

Synovial fibroblasts spread rheumatoid arthritis to unaffected joints

(2009) Stephanie Lefèvre et al.   NATURE MEDICINE

Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications

(2009) Brian D. Brown et al.   NATURE REVIEWS GENETICS

Gene therapy of the rheumatic diseases: 1998 to 2008

(2009) Christopher H Evans et al.   ARTHRITIS RESEARCH & THERAPY

Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor   antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study

(2008) P J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial

(2008) M Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

(2008) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Manufacturing and characterizing AAV-based vectors for use in clinical studies

(2008) J F Wright   GENE THERAPY

Clinical gene therapy using recombinant adeno-associated virus vectors

(2008) C Mueller et al.   GENE THERAPY

Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1

(2008) Salima Hacein-Bey-Abina et al.   JOURNAL OF CLINICAL INVESTIGATION